|
시장보고서
상품코드
2050603
내장리슈만편모충증 시장 : 약제 유형별, 투여 경로별, 제형별, 질병 단계별, 연령층별, 유통 채널별, 최종사용자별(병원), 지역별Visceral Leishmaniasis Market, By Drug Type, By Administration Route, By Dosage Form, By Disease Stage, By Age Group, By Distribution channel, By End User Hospitals, By Geography |
||||||
내장리슈만편모충증 시장은 2026년에 12억 3,000만 달러로 추정되고 있으며, 2033년까지 19억 9,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 12억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 7.10% | 2033년 시장 규모 예측 : | 19억 9,000만 달러 |
세계의 내장형 리슈만병 시장은 감염성 질환 치료제 시장에서 매우 중요한 부문를 차지하고 있으며, 내장 기관에 영향을 미치고 치료하지 않으면 심각한 사망 위험을 초래하는 가장 심각한 형태의 리슈만병 중 하나에 대응하는 시장입니다. 내장 리슈만병(칼라 아자르)은 리슈만니아 속 원충에 의해 발생하며, 감염된 암컷 바다거북의 흡혈에 의해 전파됩니다. 주로 동아프리카, 인도 아대륙, 라틴아메리카 일부를 포함한 열대 및 아열대 지역 주민들에게 영향을 미치고 있습니다. 이 질병은 의료 인프라에 대한 접근성이 제한된 빈곤 지역에 불균형적으로 영향을 미치고 있으며, 공중 보건에 심각한 문제를 야기하고 해당 지역에 경제적 부담을 주고 있습니다.
현재 치료 접근법에는 5가 안티모니, 암포테리신 B, 밀테포신, 병용요법 등 다양한 치료법이 있지만, 약제 내성, 치료 기간, 비용, 접근성 등의 문제로 인해 이 시장에서의 혁신이 계속되고 있습니다. 글로벌 시장에는 의약품, 진단 솔루션, 예방 및 지지요법 제품이 포함되어 있으며, 전 세계 환자들의 미충족 수요를 충족시키기 위해 보다 효과적이고, 저렴하며, 환자가 사용하기 쉬운 치료 옵션 개발에 점점 더 집중하고 있습니다.
시장 역학
세계의 내장 리슈만증 시장은 주로 다양한 지역적 지역에서 성장 궤도와 상업적 타당성을 형성하는 여러 가지 상호 연관된 요인에 의해 주도되고 있습니다. 전염병이 유행하는 지역, 특히 위생 인프라가 취약하고 매개체 방제 대책이 미흡한 개발도상국에서 질병 유병률이 증가함에 따라 효과적인 치료 중재 및 진단 솔루션에 대한 수요가 지속적으로 증가하고 있습니다. 의료 종사자와 국제 보건 기관들 사이에서 이 질병의 질병 부담에 대한 인식이 높아진 데다, 감시 시스템 강화와 진단 능력 향상으로 인해 사례 발견률과 치료 시작률이 향상되고 있습니다. 정부의 노력과 세계보건기구(WHO), 빌 & 멜린다 게이츠 재단 및 다양한 비정부기구(NGO)의 자금 지원은 치료비 보조 프로그램 및 새로운 치료법 개발을 위한 연구비 지원을 통해 시장 확대에 크게 기여하고 있습니다.
그러나 시장 억제요인으로는 대상 인구의 구매력 한계, 유행 지역의 의료 인프라 미비, 개발도상국의 의약품 승인을 위한 복잡한 규제 프로세스, 기존 치료법에 대한 약제 내성 발생에 따른 문제 등이 있습니다. 원격지 유행 지역에서의 제조 및 유통 문제 외에도 특정 제제에 필요한 특수한 보관 조건은 시장 접근을 더욱 제한하고 있습니다. 이러한 어려움에도 불구하고 약물전달 시스템의 기술 발전, 효능이 향상된 병용요법 개발, 저렴한 가격의 약물 접근성 프로그램을 위한 공공-민간 파트너십 확대, 현재의 치료 한계와 내성 패턴에 대응하는 차세대 치료 솔루션에 초점을 맞춘 연구 활동에 대한 투자 확대 등 R&D 활동에 대한 투자 증가를 통해 큰 기회가 존재하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 전 세계 내장형 리슈만병증 시장의 주요 업체를 분석합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 내장 리슈만증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 내장 리슈만증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 내장리슈만편모충증 시장 : 약제 유형별, 2021-2033년
제5장 세계의 내장리슈만편모충증 시장 : 투여 경로별, 2021-2033년
제6장 세계의 내장리슈만편모충증 시장 : 제형별, 2021-2033년
제7장 세계의 내장리슈만편모충증 시장 : 질병 단계별, 2021-2033년
제8장 세계의 내장리슈만편모충증 시장 : 연령층별, 2021-2033년
제9장 세계의 내장리슈만편모충증 시장 : 유통 채널별, 2021-2033년
제10장 세계의 내장리슈만편모충증 시장 : 최종사용자별, 2021-2033년
제11장 세계의 내장리슈만편모충증 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
KSA 26.06.10Visceral Leishmaniasis Market is estimated to be valued at USD 1.23 Bn in 2026 and is expected to reach USD 1.99 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.23 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.10% | 2033 Value Projection: | USD 1.99 Bn |
Global visceral leishmaniasis market represents a critical segment within the infectious disease therapeutics landscape, addressing one of the most severe forms of leishmaniasis that affects internal organs and poses significant mortality risks if left untreated. Visceral leishmaniasis, also known as kala-azar, is caused by protozoan parasites of the Leishmania species and transmitted through the bite of infected female phlebotomine sandflies, predominantly affecting populations in tropical and subtropical regions including East Africa, the Indian subcontinent, and parts of Latin America. The disease disproportionately impacts impoverished communities with limited access to healthcare infrastructure, creating substantial public health challenges and economic burden on affected regions.
Current treatment approaches encompass various therapeutic modalities including pentavalent antimonials, amphotericin B formulations, miltefosine, and combination therapies, though challenges related to drug resistance, treatment duration, cost considerations, and accessibility continue to drive innovation in this market. The global market encompasses pharmaceutical interventions, diagnostic solutions, preventive measures, and supportive care products, with increasing focus on developing more effective, affordable, and patient-friendly treatment options to address the unmet medical needs of affected populations worldwide.
Market Dynamics
The global visceral leishmaniasis market is primarily driven by several interconnected factors that shape its growth trajectory and commercial viability across different geographical regions. Increasing disease prevalence in endemic areas, particularly in developing countries with inadequate vector control measures and poor sanitation infrastructure, continues to fuel demand for effective therapeutic interventions and diagnostic solutions. Growing awareness among healthcare professionals and international health organizations about the disease burden, coupled with enhanced surveillance systems and improved diagnostic capabilities, has led to better case detection and treatment initiation rates. Government initiatives and funding from international organizations such as the World Health Organization, Bill & Melinda Gates Foundation, and various non-governmental organizations have significantly contributed to market expansion through subsidized treatment programs and research funding for novel therapeutic development.
However, the market faces substantial restraints including limited purchasing power of target populations, inadequate healthcare infrastructure in endemic regions, complex regulatory pathways for drug approval in developing countries, and challenges associated with drug resistance development against existing therapeutic options. Manufacturing and distribution challenges in remote endemic areas, along with the requirement for specialized storage conditions for certain formulations, further constrain market accessibility. Despite these challenges, significant opportunities exist through technological advancements in drug delivery systems, development of combination therapies with improved efficacy profiles, expansion of public-private partnerships for affordable drug access programs, and increasing investment in research and development activities focused on next-generation therapeutic solutions that address current treatment limitations and resistance patterns.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Visceral Leishmaniasis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Gilead Sciences, Profounda, Inc. , Novartis AG, Gsk Plc., Zydus Lifesciences Limited, and MOLOGEN AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Visceral Leishmaniasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Visceral Leishmaniasis market.
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Liposomal Amphotericin B
- Miltefosine
- Administration Route Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous
- Dosage Form (Revenue, USD Bn, 2021 - 2033)
- Capsule
- Injection
- Disease Stage Insights (Revenue, USD Bn, 2021 - 2033)
- Acute Visceral Leishmaniasis
- Chronic Visceral Leishmaniasis
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adults
- Pediatric
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Home Care Settings
- Academics and Research Institutes
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Gilead Sciences
- Profounda, Inc.
- Novartis AG
- Gsk Plc.
- Zydus Lifesciences Limited
- MOLOGEN AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Visceral Leishmaniasis Market, By Drug Type
- Global Visceral Leishmaniasis Market, By Administration Route
- Global Visceral Leishmaniasis Market, By Dosage Form
- Global Visceral Leishmaniasis Market, By Disease Stage
- Global Visceral Leishmaniasis Market, By Age Group
- Global Visceral Leishmaniasis Market, By Distribution channel
- Global Visceral Leishmaniasis Market, By End User
- Global Visceral Leishmaniasis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Visceral Leishmaniasis Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Liposomal Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Miltefosine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Visceral Leishmaniasis Market, By Administration Route, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Visceral Leishmaniasis Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Capsule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Visceral Leishmaniasis Market, By Disease Stage, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Acute Visceral Leishmaniasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Chronic Visceral Leishmaniasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Visceral Leishmaniasis Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Visceral Leishmaniasis Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Visceral Leishmaniasis Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academics and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Visceral Leishmaniasis Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Profounda, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gsk Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MOLOGEN AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
